TY - JOUR
T1 - Surgery-Related Muscle Loss after Pancreatic Resection and Its Association with Postoperative Nutritional Intake
AU - Hogenbirk, Rianne N.M.
AU - Hentzen, Judith E.K.R.
AU - van der Plas, Willemijn Y.
AU - Campmans-Kuijpers, Marjo J.E.
AU - Kruijff, Schelto
AU - Klaase, Joost M.
N1 - Funding Information:
This work is supported by a grant from the UMCG Cancer Research Foundation (Institutional Foundation for Cancer Research and Development). The study protocol has not undergone any peer-review by this funding body, nor did they play a role in the analysis and interpretation of the data.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/2/3
Y1 - 2023/2/3
N2 - To study the occurrence of surgery-related muscle loss (SRML) and its association with in-hospital nutritional intake, we conducted a prospective observational cohort study including patients who underwent pancreatic surgery because of (suspected) malignant diseases. Muscle diameter was measured by using bedside ultrasound 1 day prior to surgery and 7 days postoperatively. Clinically relevant SRML was defined as ≥10% muscle diameter loss in minimally one arm and leg muscle within 1 week after surgery. Protein and caloric intake was measured by nutritional diaries. The primary endpoint included the number of patients with SRML. Secondary endpoints included the association between SRML and postoperative nutritional intake. Of the 63 included patients (60.3% men; age 67.1 ± 10.2 years), a total of 24 patients (38.1%) showed SRML. No differences were observed in severe complication rate or length of hospital stay between patients with and without SRML. During the first postoperative week, patients with clinically relevant SRML experienced more days without any nutritional intake compared with the non-SRML group (1 [0–4] versus 0 [0–1] days, p = 0.007). Significantly lower nutritional intake was found in the SRML group at postoperative days 2, 3 and 5 (p < 0.05). Since this study shows that SRML occurred in 38.1% of the patients and most of the patients failed to reach internationally set nutritional goals, it is suggested that more awareness concerning direct postoperative nutritional intake is needed in our surgical community.
AB - To study the occurrence of surgery-related muscle loss (SRML) and its association with in-hospital nutritional intake, we conducted a prospective observational cohort study including patients who underwent pancreatic surgery because of (suspected) malignant diseases. Muscle diameter was measured by using bedside ultrasound 1 day prior to surgery and 7 days postoperatively. Clinically relevant SRML was defined as ≥10% muscle diameter loss in minimally one arm and leg muscle within 1 week after surgery. Protein and caloric intake was measured by nutritional diaries. The primary endpoint included the number of patients with SRML. Secondary endpoints included the association between SRML and postoperative nutritional intake. Of the 63 included patients (60.3% men; age 67.1 ± 10.2 years), a total of 24 patients (38.1%) showed SRML. No differences were observed in severe complication rate or length of hospital stay between patients with and without SRML. During the first postoperative week, patients with clinically relevant SRML experienced more days without any nutritional intake compared with the non-SRML group (1 [0–4] versus 0 [0–1] days, p = 0.007). Significantly lower nutritional intake was found in the SRML group at postoperative days 2, 3 and 5 (p < 0.05). Since this study shows that SRML occurred in 38.1% of the patients and most of the patients failed to reach internationally set nutritional goals, it is suggested that more awareness concerning direct postoperative nutritional intake is needed in our surgical community.
KW - muscle wasting
KW - nutrition
KW - pancreatic cancer
KW - pancreatic surgery
KW - POCUS
KW - protein intake
KW - surgery-related muscle loss
KW - ultrasound
U2 - 10.3390/cancers15030969
DO - 10.3390/cancers15030969
M3 - Article
C2 - 36765926
AN - SCOPUS:85147867686
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 3
M1 - 969
ER -